Phase I Clinical Trial for Evaluation of Pharmacokinetics, Pharmacodynamics and Safety of Testosterone Gel 1% for Topical Use, After Administration of Three Different Doses (2.2 mg, 4.4 mg, 8.8 mg and Placebo) for 28 Consecutive Days in Post-menopausal Women.

Next Previous
Trial Profile

Phase I Clinical Trial for Evaluation of Pharmacokinetics, Pharmacodynamics and Safety of Testosterone Gel 1% for Topical Use, After Administration of Three Different Doses (2.2 mg, 4.4 mg, 8.8 mg and Placebo) for 28 Consecutive Days in Post-menopausal Women.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Testosterone (Primary)
  • Indications Menopausal syndrome
  • Focus Pharmacokinetics
  • Sponsors Biolab Sanus Farmaceutica

    • Most Recent Events

    • 02 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
    • 02 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 02 Feb 2017 Planned initiation date changed from 1 Jul 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top